ABBV-IMAB-TJC4
Showing 26 - 50 of 105
Healthy Volunteers Trial (ABBV-141, Placebo for ABBV-141)
Not yet recruiting
- Healthy Volunteers
- ABBV-141
- Placebo for ABBV-141
- (no location specified)
Nov 20, 2023
Generalized Anxiety Disorder (GAD), Healthy Participants Trial in Anaheim, Grayslake (ABBV-932, Placebo)
Recruiting
- Generalized Anxiety Disorder (GAD)
- Healthy Participants
- ABBV-932
- Placebo
-
Anaheim, California
- +1 more
Feb 23, 2023
Human Immunodeficiency Virus (HIV) Trial in Puerto Rico, United States (ABBV-382, Placebo for ABBV-382)
Recruiting
- Human Immunodeficiency Virus (HIV)
- ABBV-382
- Placebo for ABBV-382
-
Bakersfield, California
- +20 more
Dec 15, 2022
Alzheimer's Disease (AD) Trial in Worldwide (ABBV-552, Placebo for ABBV-552)
Not yet recruiting
- Alzheimer's Disease (AD)
- ABBV-552
- Placebo for ABBV-552
-
Irvine, California
- +59 more
Mar 6, 2023
Healthy Volunteers Patients With Generalized Anxiety Disorder (GAD) Trial in Grayslake (ABBV-932, Placebo for ABBV-932)
Not yet recruiting
- Healthy Volunteers Patients With Generalized Anxiety Disorder (GAD)
- ABBV-932
- Placebo for ABBV-932
-
Grayslake, IllinoisAcpru /Id# 255945
Aug 30, 2023
Advanced Solid Tumors Cancer Trial in Worldwide (ABBV-368, Tilsotolimod, Nab-paclitaxel)
Active, not recruiting
- Advanced Solid Tumors Cancer
- ABBV-368
- +3 more
-
Chicago, Illinois
- +25 more
Mar 9, 2022
Healthy Volunteers Trial in Grayslake (ABBV-990, Placebo for ABBV-990)
Recruiting
- Healthy Volunteers
- ABBV-990
- Placebo for ABBV-990
-
Grayslake, IllinoisAcpru /Id# 247995
Jul 26, 2022
Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC) Trial in Worldwide (ABBV-637, Docetaxel, Osimertinib)
Recruiting
- Advanced Solid Tumors Cancer
- Non Small Cell Lung Cancer (NSCLC)
- ABBV-637
- +2 more
-
Boston, Massachusetts
- +32 more
Dec 9, 2022
Amyotrophic Lateral Sclerosis Trial (ABBV-CLS-7262 Dose 1, ABBV-CLS-7262 Dose 2, Matching Placebo)
Not yet recruiting
- Amyotrophic Lateral Sclerosis
- ABBV-CLS-7262 Dose 1
- +2 more
- (no location specified)
Feb 12, 2023
Relapsed/Refractory Multiple Myeloma Trial in Worldwide (ABBV-383, Dexamethasone, Lenalidomide)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- ABBV-383
- +5 more
-
Little Rock, Arkansas
- +45 more
Jul 8, 2022
NSCLC, Head and Neck Squamous Cell Carcinoma Trial in Israel, Japan, United States (ABBV-514, Pembrolizumab, Budigalimab)
Recruiting
- Non-Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- ABBV-514
- +2 more
-
Fullerton, California
- +13 more
Jul 11, 2022